Advances in Cystic Fibrosis: Perspectives from Phoenix 2015

Slides:

Advertisements

Similar presentations

Date of download: 6/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial to Evaluate the Efficacy of Cognitive.

Advertisements

Introduction. Practical Perspectives in the Surgical Management of Parkinson Disease: LCIG.

Site, Sponsor, CRO: Understanding Roles & Expectations Creating a Team Approach Alan Genatossio, BSN, RN Seattle Children’s, Seattle, WA Colleen.

New Horizons for SMA.

Pseudomonas Infection in Cystic Fibrosis

Silent No More:.

How the Latest Data in MDD Can Guide Treatment Decisions:

The Effect of Intra-Articular Steroids on Cartilage in Knee Osteoarthritis.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Bipolar I Depression Today: The Evolving Understanding of Bipolar Depression Neurobiology and the Relation to Diagnosis.

Renal Denervation Two Late-Breaking Clinical Trials.

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

A Paradigm Shift in PAH.

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Pseudomonas Lung Infections in Cystic Fibrosis

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Progression After Cancer Immunotherapy in Advanced NSCLC

افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی

افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی

Emergency Management of NOAC Bleeding

PAD Patients vs Post-ACS Patients:

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Part 1: Disease Activity Measures

PCP Perspectives Clinical Considerations in Hyperkalemia

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Advances in Cystic Fibrosis 2017

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Patient-Centered Care in Cystic Fibrosis

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Definitions: Seizure, Epilepsy, Epilepsy Syndrome

New Treatments for CTEPH

Oral Anticoagulants in AFa,b A Brief History.

Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016.

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Evaluating Effects of CFTR Modulation in Cystic Fibrosis

Selected Highlights of the Latest Advances in PAH

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited

Demographics of IPF in the USa-d

Oral Anticoagulation in AF

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Advancing the Treatment of IBD With Biologics

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

Treating to Target in MS

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Volume 143, Issue 1, Pages (January 2013)

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Addressing Treatment Challenges in Cystic Fibrosis

Peanut Allergy Immunotherapy

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Strategies for Infection Control in Cystic Fibrosis

Third-Generation EGFR TKIs

Issue Highlights Clinical Gastroenterology and Hepatology

Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.

Real-World Evidence.

Evaluating Success of Current Treatments for HCM

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Expert Perspectives.

NAFLD and NASH in Europe and Canada

The Power of As-Treated Analyses

Presentation transcript:

Advances in Cystic Fibrosis: Perspectives from Phoenix 2015

Advances in Cystic Fibrosis Perspectives from Phoenix 2015

Possible Interaction of Azithromycin + Tobramycin Background/Methods

Possible Interaction of Azithromycin + Tobramycin Clinical Results

Possible Interaction of Azithromycin + Tobramycin In Vitro Results

AeroVanc Phase 2 Trial

Advances in Cystic Fibrosis Perspectives from Phoenix 2015

PROGRESS Trial

PROGRESS Trial Results

PROGRESS Trial Conclusions

Pooled Analysis of TRAFFIC/TRANSPORT Design

Pooled Analysis of TRAFFIC/TRANSPORT Efficacy

Long-Term Ivacaftor in Severe CF Results

Advances in Cystic Fibrosis Perspectives from Phoenix 2015

Perceptions of Depression Screening

Dissemination of the Buffalo Approach to Depression Screening Background

Development of a Comprehensive Transition Program

“Dallas Dashboard” for Transition

Advances in Cystic Fibrosis Perspectives from Phoenix 2015

ENVISION Linear Growth With Ivacaftor

CRC Screening in CF

CRC Screening in CF Results

STOP Study

Advances in Cystic Fibrosis Perspectives from Phoenix 2015

The GOAL-E2 Study Design

The GOAL-E2 Study Changes from Baseline to 1 Month (n = 45)

The GOAL-E2 Study Implications

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)